Each year, clinical upper gastrointestinal events occur in 2 to 4 percent of patients who are taking nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We assessed whether rofecoxib, a ...

Four years later, another cousin, Raphael de Rothschild, died in Manhattan from a heroin overdose. He was just 23. For some years it appeared that Nat Rothschild, too, would follow in their ...

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year.

Pauline de Rothschild brought sophistication and flair to every aspect of her marriagethis included completely transforming her husband's famous home: Chateau Moutin. Fact or Fiction? The Legend ...

HSBC cut its rating to "reduce" from "buy," and slashed its price objective Eli Lilly And Co (NYSE:LLY) stock is 1.6% lower to trade at $870.31 at last check, after a rare double downgrade from ...

Here’s an idea for the next episode of “The Eli Manning Show.” The former quarterback visits various investors and tries to pool enough money to buy a minority ownership stake in the Giants.

The ACHIEVE-1 trial serves as a major de-risking event for the program, but we need to see consistently positive results in other trials. And in the longer term, Eli Lilly will need to consider ...

Michael Nagle / Bloomberg via Getty Images Shares of Eli Lilly (LLY) fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed first-quarter results that ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Eli Lilly's Q1 numbers showed strong revenue and earnings growth, driven by its GLP-1 offerings. The company's 2025 outlook disappointed investors, however, leading to the decline. The stock ...